Mount Pleasant, SC – According to filings with the U.S. Securities and Exchange Commission, FirstString Research is raising $30,000,000.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Guatam Ghatnekar played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About FirstString Research

FirstString Research was founded on a vision to deliver clinically relevant and effective solutions for the treatment of diseases based upon insights and understanding from the molecular and cellular contexts that define the underlying pathology. We are dedicated to delivering breakthrough solutions for inflammation and injury based medical conditions through a better understanding of the molecular and cellular contexts that define the underlying pathology. Our focus is on diseases associated with dysregulation of inflammatory processes and modulation of injury response, such as in cutaneous radiation injury, radiation dermatitis, and wounds. Inflammation is an inevitable and potentially harmful response to tissue damage or trauma and understanding the molecular basis underlying the body’s systemic inflammatory response within the context of the injury offers significant therapeutic opportunity. Our clinical development strategies are based upon insights from biological context resulting in the validation of therapeutic potential for novel indications with earlier RoI prospects.

To learn more about FirstString Research, visit http://firststringresearch.com/

Contact:
Guatam Ghatnekar, President and Chief Executive Officer
843-860-8372
ghatnekar@firststringresearch.com
https://www.linkedin.com/in/gautam-ghatnekar-5214a16/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved